Read by QxMD icon Read


Paul M Ridker, Eva Lonn, Nina P Paynter, Robert Glynn, Salim Yusuf
No abstract text is available yet for this article.
May 16, 2017: Circulation
Lucy Sanders, Margaret Donovan-Hall, Alan Borthwick, Catherine J Bowen
BACKGROUND: Despite significant advancements in new treatment modalities for rheumatoid arthritis with biological therapies, foot complications remain a disabling and common feature of the disease. In this study the aim was to explore and describe the personal experiences of people with rheumatoid arthritis in receipt of biologic treatments in a bid to understand the impact of this form of medication on their mobility. METHODS: An interpretative phenomenological analysis (IPA) was undertaken to explore in depth the individual experience of rheumatoid disease through personal accounts of the patient journey spanning both 'before' and 'after' the instigation of biologic therapy...
2017: Journal of Foot and Ankle Research
Yoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, Nobuyuki Miyasaka, Katsuyoshi Kawana, Junko Kimura, Naoki Agata, Tsutomu Takeuchi
BACKGROUND: This study was conducted to evaluate the feasibility of long-term adalimumab (ADA) discontinuation after achievement of low disease activity (LDA) in Japanese patients with early rheumatoid arthritis (RA) and to identify predictors of LDA maintenance. METHODS: In the HOPEFUL-1 study, patients received initial therapy with either ADA plus methotrexate (MTX; intensive therapy) or MTX alone (standard therapy) for 26 weeks, followed by ADA + MTX for 26 weeks...
March 14, 2017: Arthritis Research & Therapy
Deena R Levine, Belinda N Mandrell, April Sykes, Michele Pritchard, Deborah Gibson, Heather J Symons, David Wendler, Justin N Baker
Importance: Early palliative care integration for cancer patients is now touted as the optimal care model, yet significant barriers often prevent its implementation. A perceived barrier, especially for pediatric oncology patients, is the notion that patients and their families may not need or want palliative care involvement early in the disease trajectory. Objective: To determine the perception of symptom burden early in treatment and assess attitudes toward early integration of palliative care in pediatric oncology patient-parent pairs...
March 9, 2017: JAMA Oncology
Niki Katsiki, Dimitri P Mikhailidis, Costas Tsioufis
No abstract text is available yet for this article.
February 2017: Current Opinion in Lipidology
Salim Yusuf, Akbar Panju, Roman Jaeschke
No abstract text is available yet for this article.
December 23, 2016: Polskie Archiwum Medycyny Wewnętrznej
Faiçal Jarraya
Hypertension remains the most important risk factor for cardiovascular disease. If antihypertensive drugs choice is well guided today, blood pressure (BP) target still a subject of controversies. Residual risk is matter of debate and the lower- the better dogma is come back again regarding to data reported from recent trials. The J curve, reason for European Society of Hypertension Guidelines reappraisal in 2009, is criticized by recent data. The one goal (<140/90 mmHg) fit 90 mmg 90 mmHg) fit all should be adapted as a personalized goal guided by evidence generated by randomized controlled trials...
2017: Advances in Experimental Medicine and Biology
Chirag Bavishi, Sangita Goel, Franz H Messerli
Isolated systolic hypertension is the most common hemodynamic form of hypertension in the elderly. With a rapidly aging population, the prevalence of hypertension, particularly isolated systolic hypertension, is expected to increase substantially. This phenomenon of increasing systolic pressure in the elderly is believed to be secondary to pathophysiological changes of aging as well as modifiable risk factors. Isolated systolic hypertension is associated with substantial mortality and morbidity, particularly of cerebrovascular disease...
December 2016: American Journal of Medicine
Paul K Whelton, David M Reboussin, Lawrence J Fine
No abstract text is available yet for this article.
November 1, 2016: JAMA Cardiology
Ann Marie Navar, Michael J Pencina, Eric D Peterson
Importance: The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated the benefit of lowering systolic blood pressure (SBP) to 120 mm Hg, yet other trials, such as Heart Outcomes Prevention Evaluation-3 (HOPE-3), did not find consistent benefit. How to incorporate these results into the treatment of those with elevated SBP in the general population is not clear. Objectives: To assess the representativeness of SPRINT and HOPE-3 relative to patients in the United States and to explore the cardiovascular disease (CVD) risk profiles of various populations with elevated SBP...
November 1, 2016: JAMA Cardiology
Salim Yusuf, Eva Lonn
No abstract text is available yet for this article.
November 1, 2016: JAMA Cardiology
Christian Keller, Jochen Müller-Ehmsen
The HOPE-3-Trial investigated the effect of primary prevention on cardio- and neurovascular events in patients without known atherosclerotic disease, but with intermediate risk. In a factorial design Rosuvastatin 10 mg, Candesartan 16 mg/HCT 12.5 mg or both were compared with placebo. Rosuvastatin effectively lowered LDL-cholesterol and the rate of cardio- and neurovascular complications with a NNT of approximately 500/year without detectable effect on mortalitiy. Candesartan 16 mg/HCT 12.5 mg did not influence any endpoint, however, the predefined subgroup of patients with hypertension level I had a benefit...
September 2016: Deutsche Medizinische Wochenschrift
Christina M Wyatt, Glenn M Chertow
The recently published Heart Outcomes Prevention Evaluation trial (HOPE-3) demonstrated no benefit of lowering blood pressure with candesartan and hydrochlorothiazide in persons at intermediate cardiovascular risk and with adequate blood pressure control as determined by the enrolling physician. The results of Systolic Blood Pressure Intervention Trial (SPRINT) and HOPE-3 highlight the importance of considering differences in study design and patient population when interpreting the results of clinical trials...
September 2016: Kidney International
M Brunström, B Carlberg
OBJECTIVE: To assess the effect of blood pressure lowering treatment on the risk of death and cardiovascular disease at different blood pressure levels. DESIGN AND METHOD: We used data from a previous systematic review and meta-analysis of blood pressure lowering treatment, adding the results from the recently published HOPE-3 trial. The previous review standardised risk ratio and study weights according to blood pressure lowering, which has previously been associated with deranged results...
September 2016: Journal of Hypertension
Jiří Widimský
UNLABELLED: The HOPE-3 study focused on identifying the significance of the polypill and mini-polypill in broad clinical practice, including individuals of different gender without cardiovascular diseases with an intermediate risk of cardiovascular diseases. The authors were interested in the question whether people from various antropologhy groups including not only white people but also other antropologhy groups - the blacks, people of Asian and South American origin and more covering 6 continents, would respond in a similar way...
2016: Vnitr̆ní Lékar̆ství
John B Kostis, Suzanne Oparil
No abstract text is available yet for this article.
June 2016: Journal of the American Society of Hypertension: JASH
John T Wilkins, Donald M Lloyd-Jones
No abstract text is available yet for this article.
May 16, 2016: Nature Reviews. Cardiology
Sverre E Kjeldsen, Thomas Hedner, Krzysztof Narkiewicz
No abstract text is available yet for this article.
June 2016: Blood Pressure
Eva M Lonn, Jackie Bosch, Patricio López-Jaramillo, Jun Zhu, Lisheng Liu, Prem Pais, Rafael Diaz, Denis Xavier, Karen Sliwa, Antonio Dans, Alvaro Avezum, Leopoldo S Piegas, Katalin Keltai, Matyas Keltai, Irina Chazova, Ron J G Peters, Claes Held, Khalid Yusoff, Basil S Lewis, Petr Jansky, Alexander Parkhomenko, Kamlesh Khunti, William D Toff, Christopher M Reid, John Varigos, Lawrence A Leiter, Dora I Molina, Robert McKelvie, Janice Pogue, Joanne Wilkinson, Hyejung Jung, Gilles Dagenais, Salim Yusuf
BACKGROUND: Antihypertensive therapy reduces the risk of cardiovascular events among high-risk persons and among those with a systolic blood pressure of 160 mm Hg or higher, but its role in persons at intermediate risk and with lower blood pressure is unclear. METHODS: In one comparison from a 2-by-2 factorial trial, we randomly assigned 12,705 participants at intermediate risk who did not have cardiovascular disease to receive either candesartan at a dose of 16 mg per day plus hydrochlorothiazide at a dose of 12...
May 26, 2016: New England Journal of Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"